首页> Journal of leukocyte biology> At the Bench: Chimeric antigen receptor (CAR) T cell therapy for the treatment of B cell malignancies.

At the Bench: Chimeric antigen receptor (CAR) T cell therapy for the treatment of B cell malignancies.

导出 OA

翻译打印收藏纠错

第一作者： Anthony F O,Daniyan

第一单位： Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

作者： Anthony F O,Daniyan ^[1] ; Renier J,Brentjens ^[2]

作者单位： Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA. ^[1] Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA; brentjer@mskcc.org.;Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, New York, USA; and.;Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA. ^[2]

关键词 CD19 adoptive immunotherapy cellular engineering synthetic biology

医学主题词动物(Animals);抗原, CD19(Antigens, CD19);抗原, 肿瘤(Antigens, Neoplasm);B-淋巴细胞(B-Lymphocytes);人类(Humans);免疫疗法, 过继(Immunotherapy, Adoptive);白血病, B细胞(Leukemia, B-Cell);淋巴细胞活化(Lymphocyte Activation);小鼠(Mice);分子靶向治疗(Molecular Targeted Therapy);受体, 抗原, T细胞(Receptors, Antigen, T-Cell);重组融合蛋白质类(Recombinant Fusion Proteins);单链抗体(Single-Chain Antibodies);T细胞抗原受体特异性(T-Cell Antigen Receptor Specificity);T淋巴细胞, 细胞毒性(T-Lymphocytes, Cytotoxic)

DOI 10.1189/jlb.5BT1215-556RR

PMID 27789538

发布时间 2025-05-01

基金项目

R01 CA138738/CA/NCI NIH HHS/United States P01 CA059350/CA/NCI NIH HHS/United States P30 CA008748/CA/NCI NIH HHS/United States P01 CA190174/CA/NCI NIH HHS/United States K12 CA184746/CA/NCI NIH HHS/United States

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交